Scleroderma Systemic Sclerosis, SSc is a chronic, incurable autoimmune disease associated with high morbidity and mortality primarily due to lung disease. There is a large variability in individual patients courses and current predictors of disease progression are inadequate. The overall objective of the proposed research is to develop reliable predictors for clinical outcomes in scleroderma, utilizing the biospecimens and longitudinal clinical data in the GENISOS cohort combining data from multiple areas to develop robust prediction models for ILD progression. In this second year, we have focused on the measurement of serum analytes, skin gene expression studies and preparation for genotyping of GENISOS samples. We have 6 abstracts accepted for presentation at the annual American College of Rheumatology meeting Nov 7-11, 2015 in San Francisco. In addition, for the current year, we have published 9 papers with data on gene expression, genotyping and cytokine studies involving data from the GENISOS cohort that was generated through this award. We are on track with all proposed activities.